Ovensa Inc.
Verified IntelOvensa is a Canadian preclinical stage company committed to advance its siRNA lead candidate silencing galectin-1 overexpression in the tumor microenvironment to improve therapeutic outcomes of an immuno-oncology anti-PD-1 checkpoint inhibitor as a combination therapy in head & neck cancer. The company is also advancing its collaboration programs with pharmaceutical companies to develop precision and combination medicines through its proprietary TRIOZAN™ Platform for specific indications.
Ovensa is a Canadian preclinical stage company committed to advance its siRNA lead candidate silencing galectin-1 overexpression in the tumor microenvironment to improve therapeutic outcomes of an immuno-oncology anti-PD-1 checkpoint inhibitor as a combination therapy in head & neck cancer. The company is also advancing its collaboration programs with pharmaceutical companies to develop precision and combination medicines through its proprietary TRIOZAN™ Platform for specific indications.
Corporate Firmographics
Entity classification and operating profile
- Industry
- General
- Company Type
- Privately Held
- Founded
- 2012
- Employee Bracket
- 1-10
- Estimated Revenue Range
- Undisclosed
Geographic Coordinates
Headquarters address and regional territory
- Street Address
- Corporate address undisclosed
- City
- Aurora
- Region / State
- Ontario
- Postal Code
- —
- Country
- Canada
Digital Presence & Footprint
Verified domains, socials, and directory profiles
Frequently Asked Questions
Verified business inquiries and firmographic telemetry for Ovensa Inc..